Expanding the scope of a major biotech firm through a new state-of-the-art site
Biotech company BeiGene’s existing 13,000 sqm manufacturing facility in Suzhou, China, produces around 100 million tablets and capsules each year, and houses a biologics clinical development production facility. But the company’s growing commercial and clinical demands meant it needed to expand its site.
- Suzhou, Jiangsu, China
- Date started:
- Completion date:
- Client type:
- real estate
- Main services:
- advisory, controls and performance, cost and commercial management, expert opinion, procurement, programme management, project management, safety, health and quality
The company has broken ground on a new small molecule manufacturing facility in Suzhou that will have the capability to produce up to 600 million solid oral dosages annually. This supports its expanding pipeline of small molecule medicines and drug candidates as it seeks to find medicines which fight cancer.
Once complete, the new facility will significantly enhance in-house manufacturing and research and design capabilities, helping to deliver BeiGene's strategy for innovative anti-cancer medicines.
The first phase of the project includes a lab building, warehousing, production building and outdoor landscaping and bicycle storage.
We are working with BeiGene as an integrated project manager to manage the design, construction, quality, schedule, environment, health and safety, procurement and costs to make sure the project meets its objectives.
The project design is currently around 95 percent completed, and construction began in September 2021. The project is expected to achieve mechanical completion in July 2023 and finishing commissioning and qualification in January 2024.
A key employer in the region, the project will create around 300 new job opportunities for BeiGene. With strong environmental requirements, the building will meet Chinese grade two green building standards, aligning with BeiGene’s design to be a sustainable business.